Author of the publication

copy delete add this publication to your clipboard
community post
history of this post
URL
DOI
BibTeX
EndNote
APA
Chicago
DIN 1505
Harvard
MSOffice XML

Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response

S. Sapski, N. Beha, R. Kontermann, and D. Müller. Cancer Immunology Immunotherapy, (2020)
DOI: 10.1007/s00262-020-02624-6

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

Univ. -Prof. Dr. Roland Kontermann University of Stuttgart

E. Garrelts

E. Zafeiriou

Roland Weil University of Stuttgart

apl. Prof. Dr. Roland Gehrke University of Stuttgart

Other publications of authors with the same name

Pharmacokinetic Engineering of OX40-Blocking Anticalin Proteins Using Monomeric Plasma Half-Life Extension DomainsM. Siegemund, P. Oak, E. Hansbauer, A. Allersdorfer, K. Utschick, A. Winter, C. Grasmüller, G. Galler, J. Mayer, B. Weiche and 3 other author(s). Frontiers in pharmacology, (2021)An optimized antibody-single-chain TRAIL fusion protein for cancer therapyM. Siegemund, O. Seifert, M. Zarani, T. Dzinic, V. De Leo, D. Göttsch, S. Münkel, M. Hutt, K. Pfizenmaier, and R. Kontermann. mAbs, 8 (5): 879-891 (2016)Corrigendum to "Bispecific antibodies" Drug Discov. Today 20 (July (7)) (2015) 838-847R. Kontermann, and U. Brinkmann. Drug Discovery Today, 24 (7): 1422 (2019)Correction to: https://doi.org/10.1016/j.drudis.2015.02.008.Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer CellsV. Massafra, S. Tundo, A. Dietzig, A. Ducret, C. Jost, C. Klein, R. Kontermann, H. Knoetgen, M. Steegmaier, A. Romagnani and 1 other author(s). The journal of immunology, 209 (2): 493-504 (2021)Alternative antibody formats.R. Kontermann. Current opinion in molecular therapeutics, 12 (2): 176--183 (2010)The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificityO. Seifert, A. Plappert, N. Heidel, S. Fellermeier, S. Messerschmidt, F. Richter, and R. Kontermann. Protein Engineering, Design and Selection, 25 (10): 603--612 (October 2012)A novel expression and purification system for the production of enzymatic and biologically active human granzyme BM. Gehrmann, B. Doß, M. Wagner, K. Zettlitz, R. Kontermann, G. Foulds, A. Pockley, and G. Multhoff. Journal of Immunological Methods, 371 (1-2): 8--17 (2011)Monovalent TNF receptor 1-selective antibody with improved affinity and neutralizing activityF. Richter, K. Zettlitz, O. Seifert, A. Herrmann, P. Scheurich, K. Pfizenmaier, and R. Kontermann. mAbs, (September 2018)Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes.M. Rothdiener, J. Beuttler, S. Messerschmidt, and R. Kontermann. Methods in molecular biology (Clifton, N.J.), (2010)Systemic network analysis identifies XIAP and IκBα as potential drug targets in TRAIL resistant BRAF mutated melanomaG. Del Mistro, P. Lucarelli, I. Müller, S. De Landtsheer, A. Zinoveva, M. Hutt, M. Siegemund, R. Kontermann, S. Beissert, T. Sauter and 1 other author(s). npj Systems Biology and Applications, 4 (1): 39 (December 2018)

PUMA

Disambiguation of "Kontermann, Roland E."